A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

Por Lancet, Jeffrey E., Gojo, Ivana, Gotlib, Jason, Feldman, Eric J., Greer, Jacqueline, Liesveld, Jane L., Bruzek, Laura M., Morris, Lawrence, Park, Youn, Adjei, Alex A., Kaufmann, Scott H., Garrett-Mayer, Elizabeth, Greenberg, Peter L., Wright, John J., Karp, Judith E.
Publicado em 2007